Radiopharma CDMOs navigate supply chain, raw material challenges as demand goes nuclear
Novartis recently said that sales of its radiopharmaceutical Pluvicto came in lower than expected in the third quarter as a result of manufacturing issues, underscoring the tension between the explosive growth in the burgeoning market and the challenges in making these radiotherapies.
There were shortages of Pluvicto after “quality issues” were found at two manufacturing sites, and the Big Pharma had to switch production to an Italian facility and then ship the product to the US. With short half-lives of the raw materials, it only had five days to ship the therapy to patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.